Results 1 to 10 of about 185,266 (254)

The requirements of a specialist breast centre [PDF]

Breast, 2020
This article is an update of the requirements of a specialist breast centre, produced by EUSOMA and endorsed by ECCO as part of Essential Requirements for Quality Cancer Care (ERQCC) programme, and ESMO.To meet aspirations for comprehensive cancer ...
Laura Biganzoli, Fatima Cardoso, Marc Beishon, David Cameron, Luigi Cataliotti, Charlotte E. Coles, Roberto C. Delgado Bolton, Maria Die Trill, Sema Erdem, Maria Fjell, Romain Geiss, Mathijs Goossens, Christiane Kuhl, Lorenza Marotti, Peter Naredi, Simon Oberst, Jean Palussière, Antonio Ponti, Marco Rosselli Del Turco, Isabel T. Rubio, Anna Sapino, Elzbieta Senkus-Konefka, Marko Skelin, Berta Sousa, Tiina Saarto, Alberto Costa, Philip Poortmans   +26 more
doaj   +14 more sources

Comparison of specialist ataxia centres with non-specialist services in terms of care access and organisation, health services resource utilisation and costs in Germany using patient-reported data

Heliyon
Background: The ataxias are rare complex neurological disorders challenging to diagnose and manage. We explored the patient pathways, health care use and costs of individuals attending a specialist ataxia centre (SAC) compared with non–specialist ...
Julie Vallortigara, Julie Greenfield, Barry Hunt, Holm Graessner, Carola Reinhard, Andreas Nadke, Bart-Jan Schuman, Deborah Hoffman, Steve Morris, Paola Giunti   +9 more
doaj   +3 more sources

Impact of specialist ataxia centres on health service resource utilisation and costs across Europe: cross-sectional survey

Orphanet Journal of Rare Diseases, 2023
Background Little is known about the costs of treating ataxia and whether treatment at a specialist ataxia centre affects the cost of care. The aim of this study was to investigate whether patients who attended specialist ataxia centres in three European
Stephen Morris, Julie Vallortigara, Julie Greenfield, Barry Hunt, Deborah Hoffman, Carola Reinhard, Holm Graessner, Antonio Federico, Vinciane Quoidbach, Paola Giunti   +9 more
doaj   +1 more source

OUTCOME OF APLASTIC ANEMIA ACCORDING TO DISEASE SEVERITY

Hematology, Transfusion and Cell Therapy, 2023
Objective Background: Aplastic anemia is pancytopenia with a hypocellular bone marrow [
Alfadil Haroon, Syed Osman Ahmed Ahmed, Hazzaa Alzahrani, Riad El Fakih, Ali Alahmari, Alfadel Alshaibani, Naeem Chaudhri, Fahad Almohareb, Saud Alhayli, Marwan Shaheen, Abdulwahab Albabtain, Fahad Alsharif, Feras Alfraih, Walid Rasheed, Mahmoud Aljurf   +14 more
doaj   +1 more source

Co-ordinated care for people affected by rare diseases: the CONCORD mixed-methods study

Health and Social Care Delivery Research, 2022
Background: A condition is defined as rare if it affects fewer than 1 in 2000 people in the general population. Limited evidence suggests that care is poorly co-ordinated for people affected by rare conditions.
Stephen Morris, Emma Hudson, Lara Bloom, Lyn S Chitty, Naomi J Fulop, Amy Hunter, Jennifer Jones, Joe Kai, Larissa Kerecuk, Maria Kokocinska, Kerry Leeson-Beevers, Pei Li Ng, Sharon Parkes, Angus IG Ramsay, Amy Simpson, Alastair Sutcliffe, Christine Taylor, Holly Walton   +17 more
doaj   +1 more source

Observed benefits of a major trauma centre in a tertiary hospital in Nigeria

African Journal of Emergency Medicine, 2021
Introduction: A Trauma System or its components has been shown to improve trauma services and outcome of seriously injured patients. These organised services are non0existent or the components operate in isolation in most African countries.This study was
Usman Adamu Gwaram, Onyedika Godfrey Okoye, Oluwole Olayemi Olaomi   +2 more
doaj   +1 more source

Geographical challenges and inequity of healthcare access for high-risk paediatric heart disease

International Journal for Equity in Health, 2023
Background Geographical context is an important consideration for health system design to promote equality in access to care for patients with childhood heart disease (CHD), particularly those living in regional, rural, and remote areas.
Benjamin C. Auld, Bridget Abell, Prem S. Venugopal, Steven McPhail   +3 more
doaj   +1 more source

Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer

Scientific Reports, 2021
Therapeutic anti-PD-L1 antibodies are safe as a monotherapy, albeit with minimal efficacy in triple-negative breast cancer (TNBC). This trial aimed to test the safety and efficacy of Durvalumab and Paclitaxel in metastatic TNBC.
Hazem Ghebeh, Adher Al-Sayed, Riham Eiada, Leilani Cabangon, Dahish Ajarim, Kausar Suleman, Asma Tulbah, Taher Al-Tweigeri   +7 more
doaj   +1 more source

Prevalence and timing of specialist palliative care access among advanced cancer patients and association with hospital death

Proceedings of Singapore Healthcare, 2022
Background Patients with advanced cancer have poor quality of life and high utilisation of acute healthcare services. Early access to palliative care has been shown to improve quality of life as well as reduce acute healthcare utilisation and costs ...
Grace Meijuan Yang, Cindy Lim, Qingyuan Zhuang, Wah Ying Ong   +3 more
doaj   +1 more source

PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis

OncoImmunology, 2020
The T-cell inhibitory molecule PD-L1 is expressed on a fraction of breast cancer cells. The distribution of PD-L1 on the different subpopulations of breast cancer cells is not well-defined.
Fatmah A. Mansour, Amer Al-Mazrou, Falah Al-Mohanna, Monther Al-Alwan, Hazem Ghebeh   +4 more
doaj   +1 more source